Arabic Arabic English English French French German German
dark

Novo Nordisk’s ziltivekimab hits primary endpoint in CKD trial

Investigational IL-6 inhibitor reduced inflammatory biomarkers associated with atherosclerosis in CKD patients Read More

Total
0
Shares
Leave a Reply

Your email address will not be published. Required fields are marked *

Previous Post

Pandemic coincided with increase in mental health problems for children

Next Post

Merck extends oncology and autoimmunity collaboration with BioMed X

Related Posts
Total
0
Share